Your session is about to expire
← Back to Search
PARP Inhibitor
Tislelizumab + Pamiparib for Cancer
Phase 3
Waitlist Available
Research Sponsored by BeiGene
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 7 years
Awards & highlights
Study Summary
This trial is testing the long-term safety of two cancer drugs, given alone or in combination with other drugs. It includes people who have participated in a previous study.
Who is the study for?
This trial is for patients with advanced malignancies who were previously in a BeiGene study and may benefit from continued treatment. It's not for those who had severe side effects, recent serious infections, or used other cancer treatments between studies. Pregnant women and individuals with life-threatening conditions are also excluded.Check my eligibility
What is being tested?
The study tests long-term safety of Tislelizumab and/or Pamiparib alone or combined with other agents like Capecitabine, Temozolomide, etc., in participants with advanced cancers to see if they continue to help without causing new issues.See study design
What are the potential side effects?
Possible side effects include reactions at the injection site, fatigue, nausea, blood cell count changes which could lead to increased infection risk or bleeding problems. Each drug has its own profile of potential side effects that will be monitored.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 7 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 7 years
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Number of Participants with Immune-Mediated Adverse Events
Secondary outcome measures
Overall survival
Trial Design
18Treatment groups
Experimental Treatment
Group I: R - Tislelizumab and Surzebiclimab and LBL-007 Combination TherapyExperimental Treatment3 Interventions
Group II: Q - Tislelizumab and LBL-007 Combination TherapyExperimental Treatment2 Interventions
Group III: P - Tislelizumab and Zanidatamab Combination TherapyExperimental Treatment2 Interventions
Group IV: O - Tislelizumab and Lenvatinib Combination TherapyExperimental Treatment2 Interventions
Group V: N - Tislelizumab and BGB-15025 Combination TherapyExperimental Treatment2 Interventions
Group VI: M - Tislelizumab and Surzebiclimab Combination TherapyExperimental Treatment2 Interventions
Group VII: L - Tislelizumab and BGB-A445 Combination TherapyExperimental Treatment2 Interventions
Group VIII: K - Tislelizumab and Fruquintinib Combination TherapyExperimental Treatment2 Interventions
Group IX: J - Tislelizumab and BAT1706 Combination Therapy, or BAT1706 MonotherapyExperimental Treatment2 Interventions
Group X: I - Tislelizumab and Ociperlimab Combination TherapyExperimental Treatment2 Interventions
Group XI: H - Tislelizumab and Sitravatinib Combination TherapyExperimental Treatment2 Interventions
Group XII: G - Tislelizumab and Pamiparib Combination TherapyExperimental Treatment2 Interventions
Group XIII: F - Pamiparib and Temozolomide Combination TherapyExperimental Treatment2 Interventions
Group XIV: E - Zanidatamab MonotherapyExperimental Treatment1 Intervention
Group XV: D - BGB-15025 MonotherapyExperimental Treatment1 Intervention
Group XVI: C - Sitravatinib MonotherapyExperimental Treatment1 Intervention
Group XVII: B - Pamiparib MonotherapyExperimental Treatment1 Intervention
Group XVIII: A - Tislelizumab MonotherapyExperimental Treatment1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Fruquintinib
2021
Completed Phase 3
~1680
Temozolomide
2010
Completed Phase 3
~1930
Lenvatinib
2005
Completed Phase 4
~2690
Tislelizumab
2018
Completed Phase 3
~4260
Sitravatinib
2017
Completed Phase 2
~490
Ociperlimab
2021
Completed Phase 2
~530
Pamiparib
2017
Completed Phase 2
~750
BAT1706
2021
Completed Phase 3
~750
Find a Location
Who is running the clinical trial?
BeiGeneLead Sponsor
175 Previous Clinical Trials
28,525 Total Patients Enrolled
Andong Nkobena Florinas, Pharm. D.Study DirectorBeiGene
Study DirectorStudy DirectorBeiGene
1,218 Previous Clinical Trials
499,451 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I do not have an uncontrolled infection or one that needed IV drugs before the study.The doctor believes that you will still benefit from taking tislelizumab and pamiparib either alone or together.I stopped tislelizumab or pamiparib treatment due to severe side effects, not following study procedures, or withdrawing consent.I don't have any health issues that could risk my safety in the study.I haven't received any cancer treatment outside of the main study before starting the long-term extension study.I am allowed to take pamiparib for my solid tumor, except for GBM, if my doctor agrees.
Research Study Groups:
This trial has the following groups:- Group 1: G - Tislelizumab and Pamiparib Combination Therapy
- Group 2: L - Tislelizumab and BGB-A445 Combination Therapy
- Group 3: Q - Tislelizumab and LBL-007 Combination Therapy
- Group 4: A - Tislelizumab Monotherapy
- Group 5: D - BGB-15025 Monotherapy
- Group 6: E - Zanidatamab Monotherapy
- Group 7: F - Pamiparib and Temozolomide Combination Therapy
- Group 8: J - Tislelizumab and BAT1706 Combination Therapy, or BAT1706 Monotherapy
- Group 9: N - Tislelizumab and BGB-15025 Combination Therapy
- Group 10: O - Tislelizumab and Lenvatinib Combination Therapy
- Group 11: P - Tislelizumab and Zanidatamab Combination Therapy
- Group 12: R - Tislelizumab and Surzebiclimab and LBL-007 Combination Therapy
- Group 13: M - Tislelizumab and Surzebiclimab Combination Therapy
- Group 14: K - Tislelizumab and Fruquintinib Combination Therapy
- Group 15: B - Pamiparib Monotherapy
- Group 16: C - Sitravatinib Monotherapy
- Group 17: H - Tislelizumab and Sitravatinib Combination Therapy
- Group 18: I - Tislelizumab and Ociperlimab Combination Therapy
Awards:
This trial has 2 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
What is the FDA's official stance on Tislelizumab 200 mg, IV?
"Tislelizumab 200 mg, IV is considered safe based on past clinical trials and data sets."
Answered by AI
How many study participants are currently enrolled?
"Unfortunately, this particular clinical trial is not seeking new participants at this time. Although, it is worth noting that there are 889 trials for Tislelizumab 200 mg, IV enrolling patients and 2443 studies actively enrolling patients with advanced malignancies."
Answered by AI
What other similar medical trials are there to this one?
"Tislelizumab 200 mg, IV has been clinically trialed 1148 times since 2002, with 889 studies currently ongoing. The first trial, 60-patient strong, completed Phase 2 in 2002. It was sponsored by Schering-Plough."
Answered by AI
What are some other notable instances of Tislelizumab 200 mg, IV being used?
"Tislelizumab 200 mg, IV was first explored in 2002 at the Memorial Sloan Kettering Cancer Center. Since then, 1148 similar trials have been completed with 889 currently active. A large number of these active studies are being conducted in Dallas, Texas."
Answered by AI
What medical conditions does Tislelizumab 200 mg, IV typically help alleviate?
"Tislelizumab 200 mg, IV is an effective treatment for progression, disease. Additionally, it can be used to treat conditions like advanced directives, ovarian cancer, and locally advanced nonsquamous non-small cell lung cancer."
Answered by AI
Are there any unfilled appointments in this clinical trial?
"Recruitment for this clinical trial has halted. The first posting was on December 19th, 2019 with the most recent update on March 4th, 2022. However, there are 2443 other trials actively recruiting patients with advanced malignancies and 889 trials for Tislelizumab 200 mg, IV that may have open enrollment."
Answered by AI
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger